Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding Buyback Yield % Chart
New Ray Medicine International Holding Annual Data
New Ray Medicine International Holding Buyback Yield % Competitor Comparison
For the Pharmaceutical Retailers subindustry, New Ray Medicine International Holding's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
New Ray Medicine International Holding Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, New Ray Medicine International Holding's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where New Ray Medicine International Holding's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
New Ray Medicine International Holding (HKSE:06108) has a Buyback Yield % of -15.75 as of Sep. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on New Ray Medicine International Holding and its competitors. According to the industry distribution chart, New Ray Medicine International Holding ranks #200 out of 247 companies in the Healthcare Providers & Services industry, placing it in the top 81%.
Is New Ray Medicine International Holding's Buyback Yield % too high?
New Ray Medicine International Holding's current Buyback Yield % is -15.75. Based on the distribution chart, New Ray Medicine International Holding ranks #200 out of 247 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, New Ray Medicine International Holding has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does New Ray Medicine International Holding's Buyback Yield % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, New Ray Medicine International Holding ranks #200 out of 247 companies for Buyback Yield %. This places New Ray Medicine International Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on New Ray Medicine International Holding and its competitors. New Ray Medicine International Holding's current Buyback Yield % is -15.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is New Ray Medicine International Holding stock overvalued right now?
Based on GuruFocus' analysis, New Ray Medicine International Holding (HKSE:06108) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.04, compared to a current price of HK$0.24 — trading 77.1% below its estimated fair value. The current Buyback Yield % is -15.75. New Ray Medicine International Holding's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For New Ray Medicine International Holding (HKSE:06108), the current Buyback Yield % is -15.75 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?
Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued.
The current stock price of HK$0.24 is trading 77.1% below its estimated GF Value™ of HK$1.04.
GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.
Key valuation signals for HKSE:06108:
Buyback Yield %: -15.75
GF Value™: HK$1.04 vs. price of HK$0.24 (77.1% below fair value)
No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
47GF Score
Get the complete analysis for HKSE:06108
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06108 has been successfully added to your 
